

# Provider Notice



**From:** Magellan Healthcare

**Subject:** Magellan Care Guidelines update takes effect Jan. 1

## **Attention: Updated Magellan Care Guidelines for Idaho Behavioral Health Plan (IBHP)**

### **Overview**

The updated [Magellan Care Guidelines \(MCG\) for the Idaho Behavioral Health Plan \(IBHP\)](#) will be effective Jan. 1, 2025. The updated version will continue to include Magellan Healthcare Guidelines for IBHP, MCG Behavioral Health Care Guidelines (now 28<sup>th</sup> edition) developed by MCG Health® and The ASAM Criteria®, 3rd edition.

There are no substantive changes from the guidelines currently in use, except for the guideline for transcranial magnetic stimulation. Magellan is adopting the 28<sup>th</sup> edition MCG Behavioral Health Guideline “Transcranial Magnetic Stimulation” and retiring its Magellan Healthcare “Transcranial Magnetic Stimulation” clinical guideline currently in use.

This change results in:

- Slightly less restrictive clinical criteria
- Moving **from** a requirement of two failed trials from two different classes *or* inability to tolerate psychopharmacologic agents as evidenced by two trials from at least two different agent classes; **to** trials from two or more classes of antidepressants of adequate duration and dosage *or* inability to tolerate psychopharmacology as evidenced from two trials of agents with documented side effects
- Demonstrated failed trial of evidence-based psychotherapy is **no longer required**.

### **Questions**

Please contact Magellan Provider Services at [IdahoProvider@MagellanHealth.com](mailto:IdahoProvider@MagellanHealth.com).